Brief: Hookipa Announces Positive Phase 2 Interim Safety, Immunogenicity, And Efficacy Data For Its Cytomegalovirus Vaccine Candidate Hb-101

So-Young International

30/11/2020 12:21

Nov 30 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA ANNOUNCES POSITIVE PHASE 2 INTERIM SAFETY,
IMMUNOGENICITY, AND EFFICACY DATA FOR ITS CYTOMEGALOVIRUS
VACCINE CANDIDATE HB-101
    * HOOKIPA PHARMA - OBSERVED CMV-NEUTRALIZING ANTIBODY
RESPONSES &
TOLERABILITY PROFILE ARE CONSISTENT WITH PREVIOUS INTERIM
RESULTS

Source text for Eikon:  ID:nGNX6RpXP6 
Further company coverage:  HOOK.O 

 ((reuters.briefs@thomsonreuters.com;))